What databases show exact loss-of-exclusivity (LOE) dates for major drugs?
Several commercial and research-focused drug intelligence databases track patent and market-exclusivity timelines and publish (or calculate) “loss of exclusivity” dates—commonly tied to key filings, patent estates, and regulatory exclusivities. These sources are typically used to answer questions like “When will the brand’s exclusivity end?” and “When could a generic/biosimilar launch?”
Commonly used databases include:
- DrugPatentWatch.com (patent/LOE tracking)
DrugPatentWatch.com is designed around patent and exclusivity tracking and can help you find the LOE date logic used for specific products. [1]
- Derwent / Clarivate (patent data products that support exclusivity analytics)
These are frequently used for patent-family coverage and expiry analysis, which is often the backbone of LOE calculations.
- IQVIA / MIDAS and related exclusivity/payer market models
IQVIA products are often used in “market access / launch timing” workflows, where exclusivity end dates feed forecasting.
- EP/USPTO-focused aggregators and legal-monitoring databases
Patent and legal event databases (by jurisdiction) are used to compute LOE, though they usually require additional rules/translation into regulatory exclusivity dates.
Because LOE can be defined differently (patent expiry vs regulatory exclusivity vs “first permissible” generic/biosimilar approval), the exact “date” shown depends on the database’s methodology.
What determines whether a database will list “exact LOE dates” vs ranges or “earliest possible” launch windows?
Databases differ in how they translate legal/patent events into an LOE date. Exact dates generally require the provider to do all of the following:
- Map relevant patents to the correct NDA/BLA product and jurisdiction.
- Apply regulatory exclusivity rules (where tracked) rather than only patent expiry.
- Incorporate litigation status and court outcomes (which can move dates).
- Use a consistent definition of “LOE date” (e.g., earliest exclusivity termination vs earliest allowable approval vs launch permission).
If a database lacks one of those inputs, it may show a range, the “last expiring” patent, or a “possible generic entry” window instead of a single exact LOE date.
Which major companies/products are most likely covered accurately?
Coverage is strongest for widely used brands where:
- The product has well-documented patent estates and listed patents.
- Regulatory exclusivities are clearly identifiable in the jurisdiction.
- Litigation records are available and mapped to the right product.
If you’re tracking oncology biosimilars/biologics, timelines can be especially complex because exclusivity and multiple patents may overlap; databases that separately model “biosimilar entry” timing tend to be more precise than patent-only tools.
Best way to validate “exact LOE” in any database
Even when a database displays a single date, it’s worth verifying:
- What definition of LOE the database uses.
- Which specific patents/exclusivity components drive that date.
- Whether litigation or stay orders are reflected.
DrugPatentWatch.com is a starting point for checking how LOE is derived for a specific drug and date. [1]
Source to start with
DrugPatentWatch.com (patent and loss-of-exclusivity tracking for specific drugs)
[1] https://www.drugpatentwatch.com/
---
Sources:
[1] https://www.drugpatentwatch.com/